A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients



Status:Completed
Conditions:Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - Any
Updated:10/5/2018
Start Date:September 9, 2015
End Date:August 2, 2018

Use our guide to learn which trials are right for you!

A Multi-part, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Efficacy of Tropifexor (LJN452) in Patients With Primary Biliary Cholangitis

A multi-part study to assess safety, tolerability and efficacy of tropifexor (LJN452) in
patients with primary biliary cholangitis


Inclusion Criteria:

- Diagnosis of PBC as demonstrated by the presence of ≥ 2 of the following 3 diagnostic
criteria:

- History of Alkaline Phosphatase elevated above upper limit of normal for at least 6
months

- Positive anti-mitochondrial antibodies (AMA) titer or if AMA negative or in low titer
(<1:80) PBC specific antibodies (anti- GP210 and/or anti-SP100 and/or antibodies
against the major M2 components (PDC-E2, 2-oxo-glutaric acid dehydrogenase complex)

- Previous liver biopsy consistent with PBC

- At least 1 of the following markers of disease severity:

- ALP ≥ 1.67× upper limit of normal (ULN)

- Total bilirubin > ULN but < 1.5× ULN In addition, patients must meet the following
biochemical criteria at enrollment

- ALT or AST ≤ 5 × ULN

- Total bilirubin ≤ 1.5 × ULN

- INR ≤ ULN

- Subjects must weigh at least 40 kg to participate in the study, and must have a body
mass index (BMI) within the range of 18 - 40 kg/m^2. BMI = Body weight (kg) / [Height
(m)]^2.

- Able to communicate well with the investigator, to understand and comply with the
requirements of the study.

Exclusion Criteria:

- Women of child-bearing potential, defined as all women physiologically capable of
becoming pregnant, unless they are using highly effective methods of contraception
during dosing and for 30 days following end of treatment.

- History or presence of other concomitant liver diseases

- Cirrhosis with complications, including history or presence of:

- Variceal bleed

- Uncontrolled ascites

- Encephalopathy

- Spontaneous bacterial peritonitis

- Significant hepatic impairment as defined by Child-Pugh classification of B or C,
history of liver transplantation, current placement on a liver transplant list or
current Model for End Stage Liver Disease (MELD) score ≥15.

- History of conditions that may cause increases in ALP (e.g., Paget's disease).

- Use of other investigational drugs at the time of enrollment, or within 5 half-lives
of enrollment

- Elevated liver function tests at screening defined as follows:

- potential Hy's Law case (defined as ALT or AST > 3 × ULN and TBL > 2 × ULN
without notable increase in ALP to > 2 × ULN) or

- ALT or AST > 3 × ULN combined with INR > 1.5.

- Total bilirubin > ULN combined with albumin outside of the normal range.

- Currently taking obeticholic acid or have taken obeticholic acid within 30 days of
Randomization.
We found this trial at
11
sites
Miami, Florida 33136
?
mi
from
Miami, FL
Click here to add this to my saved trials
Atlanta, Georgia 30322
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Calgary, Alberta
?
mi
from
Calgary,
Click here to add this to my saved trials
Chicago, Illinois 60612
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Dallas, Texas 75216
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Manhasset, New York 11030
?
mi
from
Manhasset, NY
Click here to add this to my saved trials
Marietta, Georgia 30060
?
mi
from
Marietta, GA
Click here to add this to my saved trials
Rialto, California
?
mi
from
Rialto, CA
Click here to add this to my saved trials
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials
San Antonio, Texas 78207
Novartis Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy...
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Seattle, Washington 98103
?
mi
from
Seattle, WA
Click here to add this to my saved trials